YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.

Lei WangQuanren WangPiaopiao XuLi FuYun LiHaoyu FuHaitian QuanLiguang Lou

Published in: British journal of cancer (2020)

Our study revealed that YES1 amplification conferred resistance to HER2-targeted drugs and suggested the potential application of the strategy of combining HER2 and Yes inhibition in the clinic.

Keyphrases

nucleic acid
metastatic breast cancer
papillary thyroid
primary care
epidermal growth factor receptor
cancer therapy
positive breast cancer
type diabetes
squamous cell carcinoma
human health
risk assessment
young adults
climate change
drug induced